Cargando…

A Cost-effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-herpetic Neuralgia

Mostrar otras versiones (1)

BACKGROUND: Herpes zoster (HZ) develops in up to 50% of unvaccinated individuals, accounting for >1 million cases annually in the United States. A live attenuated HZ vaccine (LAV) is Food and Drug Administration approved for those age 50 years or older, though Advisory Committee on Immunization P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carpenter, Christopher F, Aljassem, Annas, Stassinopoulos, Jerry, Pisacreta, Giovanni, Hutton, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602903/ https://www.ncbi.nlm.nih.gov/pubmed/31289726 http://dx.doi.org/10.1093/ofid/ofz219

Ejemplares similares

A Cost-Effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-Herpetic Neuralgia
por: Carpenter, Christopher, et al.
Publicado: (2017)

Burden of herpes zoster and post-herpetic neuralgia in Sweden
por: Nilsson, Jonas, et al.
Publicado: (2015)

The impact of herpes zoster and post-herpetic neuralgia on quality-of-life
por: Johnson, Robert W, et al.
Publicado: (2010)

Herpes zoster in pregnancy leading to keloids and post herpetic neuralgia: A double whammy?
por: Verma, Shyam B., et al.
Publicado: (2013)

Assessment of the Potential Herpes Zoster and Post Herpetic Neuralgia Case Avoidance with Vaccination in the United States
por: Patterson, Brandon J, et al.
Publicado: (2017)

Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study
por: Langan, Sinéad M., et al.
Publicado: (2013)

Measuring the burden of herpes zoster and post herpetic neuralgia within primary care in rural Crete, Greece
por: Lionis, Christos D, et al.
Publicado: (2011)

Herpes zoster and severe acute herpetic neuralgia as a complication of COVID-19 infection
por: Shors, Andrew R.
Publicado: (2020)

A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK
por: Moore, Lee, et al.
Publicado: (2010)

Impact of herpes zoster and post-herpetic neuralgia on patients’ quality of life: a patient-reported outcomes survey
por: Weinke, Thomas, et al.
Publicado: (2010)

The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries
por: Lukas, Kati, et al.
Publicado: (2011)

Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study
por: Gialloreti, Leonardo Emberti, et al.
Publicado: (2010)

Persistence of a T Cell Infiltrate in Human Ganglia Years After Herpes Zoster and During Post-herpetic Neuralgia
por: Sutherland, Jeremy P., et al.
Publicado: (2019)

Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany
por: Préaud, Emmanuelle, et al.
Publicado: (2015)

Herpes Zoster and Recurrent Herpes Zoster
por: Shiraki, Kimiyasu, et al.
Publicado: (2017)

Metabolomics profiling in predicting of post-herpetic neuralgia induced by varicella zoster
por: Lu, Lina, et al.
Publicado: (2023)

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine
por: Grupping, Katrijn, et al.
Publicado: (2017)

Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study
por: Carroll, Stuart, et al.
Publicado: (2013)

Incidence of herpes zoster and post-herpetic neuralgia in Italy: Results from a 3-years population-based study
por: Alicino, Cristiano, et al.
Publicado: (2016)

Post-herpetic neuralgia
por: Tontodonati, Monica, et al.
Publicado: (2012)

The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy
por: Matthews, Sean, et al.
Publicado: (2019)

Incidence of Herpes Zoster and Persistent Post-Zoster Pain in Adults With or Without Diabetes in the United States
por: Suaya, Jose A., et al.
Publicado: (2014)

FV‐100 versus valacyclovir for the prevention of post‐herpetic neuralgia and the treatment of acute herpes zoster‐associated pain: A randomized‐controlled trial
por: Tyring, Stephen K., et al.
Publicado: (2016)

Impact of Type 1 Versus Type 2 Diabetes on Developing Herpes Zoster and Post-herpetic Neuralgia: A Population-based Cohort Study
por: WEN, Su-Ying, et al.
Publicado: (2023)

Herpes zoster ophthalmicus: Pre-eruption phase sine herpete
por: Sigireddi, Rohini R., et al.
Publicado: (2018)

Cost of Herpes Zoster in Patients With Selected Immune-Compromised Conditions in the United States
por: Li, Qian, et al.
Publicado: (2016)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
por: Schwarz, Tino F, et al.
Publicado: (2017)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Risk Factors for Herpes Zoster Among Adults
por: Marin, Mona, et al.
Publicado: (2016)

Transcriptome Analysis Reveals the Role of Cellular Calcium Disorder in Varicella Zoster Virus-Induced Post-Herpetic Neuralgia
por: Wu, Songbin, et al.
Publicado: (2021)

Trends in Hospitalizations With Primary Varicella and Herpes Zoster During the Prevaricella and Initial Postvaricella and Herpes Zoster Vaccine Eras, Connecticut, 1994–2012
por: Humes, Elizabeth A., et al.
Publicado: (2015)

Mitochondrial Haplogroups as a Risk Factor for Herpes Zoster
por: Levinson, Rebecca T., et al.
Publicado: (2016)

Botulinum as a Toxin for Treating Post-herpetic Neuralgia
por: DING, Xu-Dong, et al.
Publicado: (2017)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Trigeminal Herpes Zoster Transited to Ipsilateral Occipital Neuralgia
por: Takizawa, Keita, et al.
Publicado: (2022)

Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study
por: Berkowitz, Elchonon M., et al.
Publicado: (2015)

Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia
por: Friesen, Kevin J., et al.
Publicado: (2017)

Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults
por: You, Joyce H. S., et al.
Publicado: (2019)

Economic Burden of Herpes Zoster and Post-Herpetic Neuralgia in Adults 60 Years of Age or Older: Results from a Prospective, Physician Practice-Based Cohort Study in Kushiro, Japan
por: Nakamura, Hiroyuki, et al.
Publicado: (2017)

Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study
por: Mizukami, Akiko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bgdq112asj8hcgfp8ojsgrh114